Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00174733 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

A Phase 3 study, sponsored by Sanofi.

Completed
Registry status
Phase 3
Development phase
456
Enrollment target

NCT00174733: Completed Phase 3 study, sponsored by Sanofi.

NCT00174733 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 456 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00174733, a Phase 3 study, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 3
Development phase
456 participants
Enrollment target

Study Summary

To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.

Interventions

  • DRUG Ciclesonide (XRP1526)

Trial Details

FieldValue
Enrollment Target 456 participants
Start Date 2005-07
Est. Completion 2006-02
Phase Phase 3
Sanofi

713 total trials

What the finished NCT00174733 record still lists

NCT00174733 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).

The record links to 0 conditions, and to 1 intervention - of which Ciclesonide (XRP1526) is the first listed.

NCT00174733 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00174733 about?

NCT00174733 is a clinical study titled "Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid". To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.

What is the current status of trial NCT00174733?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2005-07. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00174733?

The interventions under investigation include: Ciclesonide (XRP1526) (DRUG).

Who is sponsoring clinical trial NCT00174733?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00174733's enrollment target sits among peer trials

456 827th of 2000 higher than 1,172 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04462302 · 456 participants · NA

    An Internet-based Program to Help Cancer Survivors Manage Pain

  • NCT05820919 · 456 participants · NA

    Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase

  • NCT06254612 · 456 participants · Phase 2

    A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  • NCT06457841 · 456 participants · NA

    Stress and Resilience

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00174733, the US trial registry maintained by the National Library of Medicine. NCT00174733 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.